Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505271 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study Using Rexin-G for Breast Cancer
A Phase 1 study, sponsored by Epeius Biotechnologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00505271: Completed Phase 1 study, sponsored by Epeius Biotechnologies.
NCT00505271 is a Phase 1 study that has completed, run by Epeius Biotechnologies. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00505271, a Phase 1 study, has completed, sponsored by Epeius Biotechnologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II registration protocol for recurrent or metastatic breast cancer.
Interventions
- GENETIC Rexin-G
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
What the finished NCT00505271 record still lists
NCT00505271 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which Rexin-G is the first listed.
NCT00505271 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00505271 about?
NCT00505271 is a clinical study titled "Safety and Efficacy Study Using Rexin-G for Breast Cancer". The goal of the adaptive trial design is to confirm the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to support a Phase II registration protocol for recurrent or metastatic breast cancer.
What is the current status of trial NCT00505271?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-07. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00505271?
The interventions under investigation include: Rexin-G (GENETIC).
Who is sponsoring clinical trial NCT00505271?
This trial is sponsored by Epeius Biotechnologies, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00505271's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia